TERUMO: MICROVENTION’S LVIS™ EVO™ INTRALUMINAL SUPPORT DEVICE NOW AVAILABLE IN THE US

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide-neck intracranial aneurysms. LVIS EVO has been available in Europe since 2019 and over 12,000 units have been sold. LVIS EVO is the first fully visible coil-assist-intracranial stent available in the US Market.

LVIS EVO delivers enhanced visualization, optimized opening and precise placement with DFT wire construction and advanced braid design. With enhanced visualization, LVIS EVO provides wall apposition confirmation. The entire body of the stent is fully visible under fluoroscopy. The optimized braid angle allows for improved device opening along the entire length of the device. With precise placement, LVIS EVO offers controlled delivery and development, as well as the ability to resheath the device up to eighty percent of the device length. The entire LVIS EVO portfolio is compatible with MicroVention’s Headway™ 17 Advanced Microcatheter and MicroVention’s Scepter C™ and Scepter XC™ Occlusion Balloons.

"I’ve really enjoyed getting to use and know EVO. With improved visibility and the ability to shelf the stent across the aneurysm neck, it’s become my tool of choice for stent-assisted coiling," said Dr. Charles Matouk, Vice Chair of the Department of Neurosurgery at Yale University.